July 10, 2020 (Latest Update)

COVID-19 Resources: Telehealth, Updates and More

AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.


Pharmaceutical company Takeda has announced the recall of the its parathyroid hormone for injection, NATPRA.


When it comes to optimal bone health and fracture prevention, there is scant evidence for recommending supplementation with vitamins and minerals other than calcium and vitamin D, according to AACE member Daniel L. Hurley, MD, FACE, who spoke at the AACE 28th Annual Scientific & Clinical Congress.


Abaloparatide followed by alendronate treatment may improve bone mineral density (BMD) in women with postmenopausal osteoporosis and type 2 diabetes (T2D), according to study results presented at the AACE 28th Annual Scientific & Clinical Congress. 


Among patients on hemodialysis, trabecular bone score was helpful in predicting fracture risk, researchers reported during an oral presentation of the findings at AACE’s 28th Annual Scientific & Clinical Congress.


AACE Member Felicia Cosman, MD, professor of medicine at Columbia University, New York, discussed the current state of osteoporosis treatment in an interview at AACE’s 28th Annual Scientific & Clinical Congress.


Dietary supplements often are sold on the promise that they will strengthen bones or even prevent osteoporosis. However, according to a new position statement released today by the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE), the current understanding of the benefits of dietary supplements on bone health are inconclusive and require further studies.